|
Aug 8
|
Vaxart CEO Issues Letter to Stockholders
|
|
Aug 7
|
The Beauty Health Company (SKIN) Surpasses Q2 Earnings and Revenue Estimates
|
|
Aug 6
|
Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13
|
|
Jul 31
|
Select Medical (SEM) Surpasses Q2 Earnings and Revenue Estimates
|
|
Jul 24
|
Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq
|
|
Jul 8
|
Vaxart Announces Trading on OTCQX Best Market
|
|
Jul 8
|
OTC Markets Group Welcomes Vaxart, Inc. to OTCQX
|
|
Jun 13
|
Vaxart Announces Preliminary Results of Annual Meeting of Stockholders
|
|
Jun 11
|
Vaxart Jumps 38% After Positive Norovirus Trial
|
|
Jun 11
|
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
|
|
May 28
|
Vaxart Answers Additional Frequently Asked Questions from Retail Investors
|
|
May 27
|
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
|
|
May 21
|
Vaxart Announces Adjournment of Annual Meeting of Stockholders
|
|
Apr 16
|
Vaxart to Present at World Vaccine Congress Washington 2025 on April 23
|
|
Oct 9
|
Vaxart Inc (VXRT) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Advances
|
|
Sep 30
|
Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
|
|
Aug 28
|
Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia
|
|
Aug 15
|
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
|
|
Aug 11
|
Vaxart Second Quarter 2024 Earnings: Misses Expectations
|
|
Jun 22
|
While institutions invested in Vaxart, Inc. (NASDAQ:VXRT) benefited from last week's 23% gain, retail investors stood to gain the most
|